Picture map of Europe with pins indicating European capital cities

Open Access research with a European policy impact...

The Strathprints institutional repository is a digital archive of University of Strathclyde's Open Access research outputs. Strathprints provides access to thousands of Open Access research papers by Strathclyde researchers, including by researchers from the European Policies Research Centre (EPRC).

EPRC is a leading institute in Europe for comparative research on public policy, with a particular focus on regional development policies. Spanning 30 European countries, EPRC research programmes have a strong emphasis on applied research and knowledge exchange, including the provision of policy advice to EU institutions and national and sub-national government authorities throughout Europe.

Explore research outputs by the European Policies Research Centre...

Prescribing restrictions - a necessary strategy among some European countries to enhance future prescribing efficiency?

Godman, Brian and Malmstrom, Rickard and Bennie, Marion (2012) Prescribing restrictions - a necessary strategy among some European countries to enhance future prescribing efficiency? Reviews in Health Care, 3 (1). pp. 5-16.

Full text not available in this repository. Request a copy from the Strathclyde author

Abstract

The unsustainable growth in pharmaceutical expenditure has resulted in multiple initiatives across Europe to lower prices of generics and enhance their utilisation. These include prescribing restrictions. However, there have been concerns with their impact on subsequent quality of care as well as their influence in reality. Aims to review the influence of prescribing restrictions and whether there are any differences depending on their nature and drug classes; ascertain whether prescribing restrictions can be added to existing demand-side measures to further enhance prescribing efficiency; discover whether they compromise subsequent quality of care. Prescribing restrictions have a variable impact on subsequent utilisation of patented protected products versus generics in a class, with their influence depending on the nature and follow-up of the restrictions rather than the class of drug. This is seen among the proton pump inhibitors, statins, and renin-angiotensin drugs. Prescribing restrictions can be successfully added to existing measures to further enhance prescribing efficiency, and do not appear to compromise subsequent quality of care. Prescribing restrictions can be a successful strategy as countries strive to maintain the European ideals for healthcare. However, care is needed when planning these programmes: else health authorities could be disappointed with their outcome.